Get the Stockscreener App
3.47
4.93%
-0.18
Briacell Therapeutics Corp stock is traded at $3.47, with a volume of 31,399.
It is down -4.93% in the last 24 hours and down -5.45% over the past month.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
See More
Previous Close:
$3.65
Open:
$3.64
24h Volume:
31,399
Relative Volume:
0.10
Market Cap:
$12.87M
Revenue:
-
Net Income/Loss:
$-16.60M
P/E Ratio:
-3.8989
EPS:
-0.89
Net Cash Flow:
$-23.48M
1W Performance:
-15.16%
1M Performance:
-5.45%
6M Performance:
-71.44%
1Y Performance:
-91.83%
1-Day Range:
$3.44
$3.7799
1-Week Range:
$3.44
$4.36
52-Week Range:
$3.09
$45.45
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
3.47 | 12.87M | 0 | -16.60M | -23.48M | -0.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
(BCT) Technical Patterns and Signals (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Short Interest Update - Defense World
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference - GlobeNewswire
BriaCell to Showcase Cancer Immunotherapy Advances at AACR 2025 - TipRanks
New Clinical Data: BriaCell's Registration Trial Results for Advanced Breast Cancer Treatment - Stock Titan
Where Will Rigetti Computing Stock Be in 1 Year? - The Globe and Mail
Dan Ives Is Pounding the Table on Microsoft Stock. Should You Buy the Dip? - The Globe and Mail
Quantum Gamble? Is IonQ's Stock an Opportunity or a Mirage? - The Globe and Mail
(BCT) Stock Evaluation Report (BCT:CA) - Stock Traders Daily
(BCT) Market Dynamics and Trading Signals (BCT:CA) - news.stocktradersdaily.com
What To Expect From Carnival’s (CCL) Q1 Earnings - The Globe and Mail
BriaCell’s Phase 3 Breast Cancer Trial Proceeds After Safety Review By Investing.com - Investing.com South Africa
Stocks In Play: BriaCell Therapeutics Corp By Baystreet.ca - Investing.com Canada
(BCT) Technical Analysis and Trading Signals (BCT:CA) - Stock Traders Daily
BriaCell Therapeutics Corp - Baystreet.ca
Stocks in play: BriaCell Therapeutics Corp - The Globe and Mail
BriaCell Therapeutics Says Data Safety Monitoring Board Recommends Continuation of Phase 3 Trial in Metastatic Breast Cancer - MarketScreener
BriaCell’s Phase 3 Metastatic Breast Cancer Study Receives Positive DSMB Review - TipRanks
BriaCell’s Phase 3 Breast Cancer Trial Proceeds After Safety Review - Investing.com
Second Data Safety Monitoring Board Issues Positive - GlobeNewswire
Major Milestone: BriaCell's Breast Cancer Immunotherapy Passes Critical Safety Review in Phase 3 Trial - Stock Titan
3 Reasons DRS is Risky and 1 Stock to Buy Instead - The Globe and Mail
Briacell Therapeutics Corp reports results for the quarter ended January 31Earnings Summary - TradingView
BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Sees Significant Growth in Short Interest - Defense World
Briacell Therapeutics Corp expected to post a loss of $1.12 a shareEarnings Preview - TradingView
3 Industrials Stocks Walking a Fine Line - The Globe and Mail
BriaCell Therapeutics (OTCMKTS:BCTXF) Trading 0.3% Higher – Here’s Why - Defense World
BriaCell Therapeutics Reports Continued Financial Challenges - TipRanks
BriaCell subsidiary reports interim financial results By Investing.com - Investing.com Australia
BriaCell Therapeutics Corp. SEC 10-Q Report - TradingView
BriaCell subsidiary reports interim financial results - Investing.com India
BriaCell Therapeutics (BCTX) Projected to Post Quarterly Earnings on Monday - Defense World
BCTX stock touches 52-week low at $3.31 amid sharp annual decline By Investing.com - Investing.com South Africa
BCTX stock touches 52-week low at $3.31 amid sharp annual decline - Investing.com
BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Significant Increase in Short Interest - Defense World
BriaCell Therapeutics (NASDAQ:BCTX) versus Actinium Pharmaceuticals (NYSE:ATNM) Critical Analysis - Defense World
BriaCell Therapeutics: Stocks Undervalued by Analyst Consensus on TSX (BCT) - The Globe and Mail
Dye & Durham Limited - Baystreet.ca
(BCT) Equity Trading Insights (BCT:CA) - Stock Traders Daily
(BCT) Market Performance Analysis (BCT:CA) - Stock Traders Daily
BriaCell Therapeutics Corp (NASDAQ: BCTX) – An Analysis Is What You Need - Stocks Register
(BCT) Investment Analysis (BCT:CA) - Stock Traders Daily
(BCT) Trading Advice (BCT:CA) - Stock Traders Daily
BriaCell Therapeutics: A Biotech Stock on the Brink of a Turnaround? - HPBL
Biotechs on the Brink: 2 Stocks With Huge Potential - MarketBeat
BriaCell regains Nasdaq compliance with bid price By Investing.com - Investing.com Australia
BriaCell regains Nasdaq compliance with bid price - MSN
Briacell Therapeutics CorpRegains Compliance With Nasdaq Minimum Bid Price Requirement - Marketscreener.com
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.89%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):